- Meta-analysis confirms BCL2 is an independent prognostic marker in breast cancerGrace M Callagy
Department of Pathology, National University of Ireland, Galway, Clinical Science Institute, Costello Road, Galway, Ireland
BMC Cancer 8:153. 2008..Here, we present the results of a meta-analysis of the association between BCL2 expression and both disease free survival (DFS) and overall survival (OS) in female breast cancer...
- Bcl-2 is a prognostic marker in breast cancer independently of the Nottingham Prognostic IndexGrace M Callagy
Cancer Genomics Program, Department of Oncology, Hutchison Medical Research Council Research Centre, University of Cambridge, United Kingdom
Clin Cancer Res 12:2468-75. 2006..We validated the results in an independent series. Experimental Design and..
- A recurrent chromosome breakpoint in breast cancer at the NRG1/neuregulin 1/heregulin geneHuai En Huang
Cancer Genomics Program, Hutchison MRC Research Centre, Department of Pathology, University of Cambridge, Cambridge, United Kingdom
Cancer Res 64:6840-4. 2004..They were, like breast tumors in general, mainly ErbB2 low (11 of 13 were low) and estrogen receptor positive (11 of 13 positive)...